Phase III looms for ProFibrix's new blood clotting drug
This article was originally published in Scrip
A US multicentre Phase II trial of ProFibrix's Fibrocaps has met all its endpoints. "We plan to initiate a pivotal Phase III trial in H1 2012 and target a BLA filing in 2013," said Jan Öhrström, CEO of the Dutch firm.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.